Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling

Area of Science:

• Computational Biology
• Pharmacology
• Cancer Research

Background:

• Conventional anti-cancer drugs often yield limited tumor reduction and temporary responses.
• Combining therapeutic agents has shown promise for improved tumor control and patient survival.
• Existing methods for evaluating drug combinations face challenges in scalability, resolution, and statistical analysis.

Purpose of the Study:

• To develop a novel theoretical framework for identifying synergistic drug combinations using high-throughput screening data.
• To model cellular viability as a stochastic lifetime process to predict combination efficacy.
• To provide a scalable and statistically robust tool for synergy assessment in cancer therapy.

Main Methods:

• Developed a theoretical framework based on stochastic lifetime modeling of cellular viability.
• Applied the method to high-throughput screening data from chemical perturbations of 65 cancer cell lines treated with two inhibitors.
• Analyzed synergy by comparing combination effects against individual agent effects within the framework.

Main Results:

• Identified synergistic efficacy for the tested drug combination in specific subsets of cancer cell lines.
• Observed no synergy in cell lines where single-agent inhibition was sufficient for cell death, aligning with signaling network topology.
• Demonstrated the utility of the method in a practical high-throughput screening context.

Conclusions:

• The developed computational tool accurately measures synergy strength for drug combinations.
• This method can aid in defining cancer signaling pathway topologies.
• The findings can guide the selection of effective drug combinations for clinical trials and personalized cancer therapy.